دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Quality control and childhood cancer medicines
doi : 10.1016/S1470-2045(23)00068-2
Volume 24, Issue 3, March 2023, Page 195
Cancer no longer a priority for England?
doi : 10.1016/S1470-2045(23)00069-4
Volume 24, Issue 3, March 2023, Page 195
Early-stage classical Hodgkin lymphoma in children and adolescents: when can radiotherapy be safely omitted?
Maurizio Mascarin
doi : 10.1016/S1470-2045(23)00058-X
Volume 24, Issue 3, March 2023, Pages 196-197
Accumulating long-term evidence for partial breast irradiation
*Icro Meattini, Charlotte E Coles
doi : 10.1016/S1470-2045(23)00062-1
Volume 24, Issue 3, March 2023, Pages 198-199
De-escalation in low-risk, HER2-positive breast cancer
Elena Geuna, Giuseppe Curigliano, * Filippo Montemurro
doi : 10.1016/S1470-2045(23)00064-5
Volume 24, Issue 3, March 2023, Pages 200-201
Endometrial cancer: the individual approach
Melanie E Powell
doi : 10.1016/S1470-2045(23)00055-4
Volume 24, Issue 3, March 2023, Pages 201-203
Modernising the US FDA's Accelerated Approval pathway
*David J Benjamin, Mark P Lythgoe
doi : 10.1016/S1470-2045(23)00020-7
Volume 24, Issue 3, March 2023, Pages 203-205
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer
Kazuki Nozawa, Masataka Sawaki, Hiroji Iwata
doi : 10.1016/S1470-2045(23)00014-1
Volume 24, Issue 3, March 2023, Page e103
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply
Stephen R D Johnston, Valérie André
doi : 10.1016/S1470-2045(23)00065-7
Volume 24, Issue 3, March 2023, Page e104
Concerns about alarmist portrayal of CT scans
Cynthia H McCollough, Mahadevappa Mahesh, Ehsan Samei
doi : 10.1016/S1470-2045(22)00762-8
Volume 24, Issue 3, March 2023, Page e105
US lawmakers call on Biden Administration to lower the price of enzalutamide
Bryant Furlow
doi : 10.1016/S1470-2045(23)00023-2
Volume 24, Issue 3, March 2023, Page 206
International Atomic Energy Agency safety missions to Fukushima
Manjulika Das
doi : 10.1016/S1470-2045(23)00050-5
Volume 24, Issue 3, March 2023, Page 207
NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma
Emma Wilkinson
doi : 10.1016/S1470-2045(23)00054-2
Volume 24, Issue 3, March 2023, Page 208
Helping patients with cancer in Türkiye and Syria
Manjulika Das
doi : 10.1016/S1470-2045(23)00071-2
Volume 24, Issue 3, March 2023, Page e107
Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?
Nicolas André, Guy Buyens, Eric Bouffet, David Walker, Matthew D Dun
doi : 10.1016/S1470-2045(23)00070-0
Volume 24, Issue 3, March 2023, Pages 209-212
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Janet E Brown, Kara-Louise Royle, Walter Gregory, Christy Ralph, Anthony Maraveyas, Omar Din, Timothy Eisen, Paul Nathan, Tom Powles, Richard Griffiths, Robert Jones, Naveen Vasudev, Matthew Wheater, Abdel Hamid, Tom Waddell, Rhona McMenemin, Poulam Patel, James Larkin, Guy Faust, Adam Martin, Jayne Swain, Janine Bestall, Christopher McCabe, David Meads, Vicky Goh, Tze Min Wah, Julia Brown, Jenny Hewison, Peter Selby, Fiona Collinson, on behalf of the STAR Investigators
doi : 10.1016/S1470-2045(22)00793-8
Volume 24, Issue 3, March 2023, Pages 213-227
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler, Naveen S Basappa, MarÃa José Méndez-Vidal, Sergei Tjulandin, Se Hoon Park, Bohuslav Melichar, Thomas Hutson, Carlos Alemany, Bradley McGregor, Thomas Powles, Viktor Grünwald, Boris Alekseev, Sun Young Rha, Evgeny Kopyltsov, Anil Kapoor, Teresa Alonso Gordoa, Jeffrey C Goh, Michael Staehler, Jaime R Merchan, Ran Xie, Rodolfo F Perini, Kalgi Mody, Jodi McKenzie, Camillo G Porta
doi : 10.1016/S1470-2045(23)00049-9
Volume 24, Issue 3, March 2023, Pages 228-238
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis
Hisham Mehanna*, Miren Taberna*, Christian von Buchwald, Sara Tous, Jill Brooks, Marisa Mena, Francisca Morey, Christian Grønhøj, Jacob Høygaard Rasmussen, Martin Garset-Zamani, Laia Bruni, Nikolaos Batis, Ruud H Brakenhoff, C René Leemans, Robert J Baatenburg de Jong, Jens Peter Klussmann, Nora Wuerdemann, Steffen Wagner, Tina Dalianis, Linda Marklund, Haïtham Mirghani, Andrew Schache, Jaqueline A James, Shao Hui Huang, Brian O’Sullivan, Paul Nankivell, Martina A Broglie, Markus Hoffmann, Elgar Susanne Quabius, Laia Alemany, on behalf of the HNCIG-EPIC group
doi : 10.1016/S1470-2045(23)00013-X
Volume 24, Issue 3, March 2023, Pages 239-251
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study
Christine Mauz-Körholz*, Judith Landman-Parker*, Ana Fernández-Teijeiro*, Andishe Attarbaschi, Walentyna Balwierz, Jörg M Bartelt, Auke Beishuizen, Sabah Boudjemaa, Michaela Cepelova, Francesco Ceppi, Alexander Claviez, Stephen Daw, Karin Dieckmann, Alexander FossÃ¥, Stefan Gattenlöhner, Thomas Georgi, Lisa L Hjalgrim, Andrea Hraskova, Jonas Karlén, Lars Kurch, Thierry Leblanc, Georg Mann, Francoise Montravers, Jane Pears, Tanja Pelz, Vladan Rajić, Alan D Ramsay, Dietrich Stoevesandt, Anne Uyttebroeck, Dirk Vordermark, Dieter Körholz†, Dirk Hasenclever†, William H Wallace†, Regine Klugeâ€
doi : 10.1016/S1470-2045(23)00019-0
Volume 24, Issue 3, March 2023, Pages 252-261
Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial
Vratislav Strnad*, Csaba Polgár*, Oliver J Ott, Guido Hildebrandt, Daniela Kauer-Dorner, Hellen Knauerhase, Tibor Major, Jarosław �yczek, Jose Luis Guinot, Cristina Gutierrez Miguelez, Pavel Slampa, Michael Allgäuer, Kristina Lössl, Bülent Polat, Rainer Fietkau, Annika Schlamann, Alexandra Resch, Anna Kulik, Leo Arribas, Peter Niehoff, Ferran Guedea, Jürgen Dunst, Christine Gall, Wolfgang Uter, on behalf of the Groupe Européen de Curiethérapie and European Society for Radiotherapy and Oncology
doi : 10.1016/S1470-2045(23)00018-9
Volume 24, Issue 3, March 2023, Pages 262-272
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, Guillermo Villacampa, Chau T Dang, Denise A Yardley, Beverly Moy, P Kelly Marcom, Kathy S Albain, Hope S Rugo, Matthew J Ellis, Iuliana Shapira, Antonio C Wolff, Lisa A Carey, Romualdo Barroso-Sousa, Patricia Villagrasa, Michelle DeMeo, Molly DiLullo, Jorge Gomez Tejeda Zanudo, Jakob Weiss, Nikhil Wagle, Ann H Partridge, Adrienne G Waks, Clifford A Hudis, Ian E Krop, Harold J Burstein, Aleix Prat, Eric P Winer
doi : 10.1016/S1470-2045(23)00051-7
Volume 24, Issue 3, March 2023, Pages 273-285
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, Laura Arenare, Carmela Pisano, Davide Lombardi, Ugo De Giorgi, Claudia Andreetta, Saverio Cinieri, Carmine De Angelis, Domenico Priolo, Claudia Casanova, Marta Rosati, Filippo Greco, Elena Zafarana, Ilaria Schiavetto, Serafina Mammoliti, Sabrina Chiara Cecere, Vanda Salutari, Simona Scalone, Alberto Farolfi, Marilena Di Napoli, Domenica Lorusso, Piera Gargiulo, Daniela Califano, Daniela Russo, Anna Spina, Rossella De Cecio, Paolo Chiodini, Francesco Perrone, on behalf of the MITO investigators
doi : 10.1016/S1470-2045(23)00016-5
Volume 24, Issue 3, March 2023, Pages 286-296
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
Thomas Walter, Astrid Lievre, Romain Coriat, David Malka, Farid Elhajbi, Fréderic Di Fiore, Olivia Hentic, Denis Smith, Vincent Hautefeuille, Guillaume Roquin, Marine Perrier, Laetitia Dahan, Victoire Granger, Iradj Sobhani, Laurent Mineur, Patricia Niccoli, Eric Assenat, Jean-Yves Scoazec, Karine Le Malicot, Côme Lepage, Catherine Lombard-Bohas
doi : 10.1016/S1470-2045(23)00001-3
Volume 24, Issue 3, March 2023, Pages 297-306
Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Matthew J Ehrhardt*, Jan M Leerink*, Renée L Mulder, Annelies Mavinkurve-Groothuis, Wouter Kok, Anju Nohria, Paul C Nathan, Remy Merkx, Esmée de Baat, Ogechukwu A Asogwa, Roderick Skinner, Hamish Wallace, E A M Lieke Feijen, Maëlle de Ville de Goyet, Maya Prasad, Edit Bárdi, Vesna Pavasovic, Helena van der Pal, Brice Fresneau, Charlotte Demoor-Goldschmidt, Ulrike Hennewig, Julia Steinberger, Chris Plummer, Ming Hui Chen, Arco J Teske, Nadia Haddy, Elvira C van Dalen, Louis S Constine, Eric J Chow, Gill Levitt, Melissa M Hudson, Leontien C M Kremer†, Saro H Armenianâ€
doi : 10.1016/S1470-2045(23)00012-8
Volume 24, Issue 3, March 2023, Pages e108-e120
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
Stephanie G C Kroeze*, Matea Pavic*, Karin Stellamans, Yolande Lievens, Carlotta Becherini, Marta Scorsetti, Filippo Alongi, Umberto Ricardi, Barbara Alicja Jereczek-Fossa, Paulien Westhoff, Jasna But-Hadzic, Joachim Widder, Xavier Geets, Samuel Bral, Maarten Lambrecht, Charlotte Billiet, Igor Sirak, Sara Ramella, Ivaldi Giovanni Battista, Sergi Benavente, Almudena Zapatero, Fabiola Romero, Thomas Zilli, Kaouthar Khanfir, Hossein Hemmatazad, Berardino de Bari, Desiree N Klass, Shaukat Adnan, Heike Peulen, Juan Salinas Ramos, Michiel Strijbos, Sanjay Popat, Piet Ost, Matthias Guckenberger
doi : 10.1016/S1470-2045(22)00752-5
Volume 24, Issue 3, March 2023, Pages e121-e132
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop
Lalitha K Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V Knopp, Richard L Wahl, Benjamin M Ellingson, Nathan C Hall, Martin J Yaffe, Alexander J Towbin, Michael D Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M Wu, David Leung, Elisabeth G E de Vries, Ying Tang, Gillian Beach, Steven A Reeves
doi : 10.1016/S1470-2045(22)00742-2
Volume 24, Issue 3, March 2023, Pages e133-e143
Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE
Volume 24, Issue 3, March 2023, Page e144
doi : 10.1016/S1470-2045(22)00744-6
Volume 24, Issue 3, March 2023, Page e144
